- Home
- VNRX
VNRX
VolitionRX Limited
as 07-08-2024 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 58.6M | IPO Year: | N/A |
| Target Price: | $2.83 | AVG Volume (30 days): | 87.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $1.55 | Next Earning Date: | 08-12-2024 |
| Revenue: | $797,029 | Revenue Growth: | 133.06% |
| Revenue Growth (this year): | 269.28% | Revenue Growth (next year): | 380.27% |
Stock Insider Trading Activity of VolitionRX Limited (VNRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Eight Corp Ltd | VNRX | 10% Owner | Jan 2 '24 | Sell | $0.90 | 20,000 | $18,000.00 | 298,419 | SEC Form 4 |
| Butera Salvatore Thomas | VNRX | CEO - Volition Veterinary | Dec 18 '23 | Buy | $0.83 | 10,000 | $8,300.00 | 99,350 | SEC Form 4 |
| Eight Corp Ltd | VNRX | 10% Owner | Dec 15 '23 | Sell | $0.75 | 20,000 | $15,000.00 | 318,419 | SEC Form 4 |
| Butera Salvatore Thomas | VNRX | CEO - Volition Veterinary | Dec 15 '23 | Buy | $0.77 | 10,000 | $7,700.00 | 89,350 | SEC Form 4 |
| Rootsaert Rodney Gerard | VNRX | Secretary | Dec 13 '23 | Buy | $0.60 | 10,000 | $6,000.00 | 78,652 | SEC Form 4 |
| Innes Guy Archibald | VNRX | Director | Nov 27 '23 | Buy | $0.77 | 20,000 | $15,400.00 | 627,161 | SEC Form 4 |
| Futcher Edward | VNRX | Director | Nov 27 '23 | Buy | $0.80 | 9,000 | $7,200.00 | 71,936 | SEC Form 4 |
| Innes Guy Archibald | VNRX | Director | Nov 24 '23 | Buy | $0.76 | 10,000 | $7,600.00 | 607,161 | SEC Form 4 |
| Innes Guy Archibald | VNRX | Director | Nov 22 '23 | Buy | $0.71 | 20,000 | $14,200.00 | 597,161 | SEC Form 4 |
Latest VolitionRX Limited News
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
Zacks Small Cap Research
14 days ago
VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Distribution of Nu.Q Vet Test Expected to Expand During 2H 2024; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture-PCR) 2) Nu.Q NET for Sepsis
ACCESSWIRE
24 days ago
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Yahoo Finance Video
a month ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
a month ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
a month ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
a month ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
a month ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Share on Social Networks:
Disclaimer
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.